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Abstract Background The quality of pharmaceutical care
in community pharmacies in the Netherlands has been
assessed annually since 2008. The initial set has been
further developed with pharmacists and patient organiza-
tions, the healthcare inspectorate, the government and
health insurance companies. The set over 2012 was the first
set of quality indicators for community pharmacies which
was validated and supported by all major stakeholders. The
aims of this study were to describe the validated set of
quality indicators for community pharmacies and to report
their scores over 2012. In subanalyses the score develop-
ment over 5 years was described for those indicators, that
have been surveyed before and remained unchanged.
Methods Community pharmacists in the Netherlands were
invited in 2013 to provide information for the set of 2012.
Quality indicators were mapped by categories relevant for
pharmaceutical care and defined for structures, processes
and dispensing outcomes. Scores for categorically-mea-
sured quality indicators were presented as the percentage of
pharmacies reporting the presence of a quality aspect. For
numerical quality indicators, the mean of all reported
scores was expressed. In subanalyses for those indicators
that had been questioned previously, scores were collected
from earlier measurements for pharmacies providing their
scores in 2012. Multilevel analysis was used to assess the
consistency of scores within one pharmacy over time by
the intra-class correlation coefficient (ICC). Results For the
set in 2012, 1739 Dutch community pharmacies (88 % of
the total) provided information for 66 quality indicators in
10 categories. Indicator scores on the presence of quality
structures showed relatively high quality levels. Scores for
processes and dispensing outcomes were lower. Subanal-
yses showed that overall indicators scores improved within
pharmacies, but this development differed between phar-
macies. Conclusions A set of validated quality indicators
provided insight into the quality of pharmaceutical care in
the Netherlands. The quality of pharmaceutical care
improved over time. As of 2012 quality structures were
present in at least 80 % of the community pharmacies.
Variation in scores on care processes and outcomes
between individual pharmacies and over time can initiate
future research to better understand and facilitate quality
improvement in community pharmacies.
Keywords Community pharmacies  Pharmaceutical
care  Quality improvement  Quality indicators 
The Netherlands
Impacts on practice
• A validated set of indicators is useful to measure
pharmaceutical care in community pharmacies.
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• A set of practice indicators is best compiled in
cooperation with pharmacists and external stakeholders
e.g. healthcare inspectorate, patient organizations and
health insurers.
• Measurement of indicators in pharmacy practice and
feedback of indicator scores results in overall score
improvement.
• Further research is needed to better understand and
facilitate quality improvement in individual
pharmacies.
Introduction
Quality indicators in healthcare address measurable aspects
of relevant systems, processes and outcomes. They provide
insight into the performance of care providers and are used
to stimulate continuous improvement of patient care [1].
Various quality indicator sets have been introduced
throughout the western world [2–6]. Among others these
sets are used to assess and improve the quality of medical
practice [7, 8].
To assess pharmaceutical care as the pharmacist’s con-
tribution to the care of individuals in order to optimize
medicines use and improve health outcomes [9], in 2008 a
national set of quality indicators has been established for
community pharmacies in the Netherlands [10]. This was
initiated by the Royal Dutch Pharmacists Association
(KNMP) and the Netherlands Healthcare Inspectorate. The
initial aims of the 2008 indicators were to gain insight into
the quality of pharmaceutical services for supervision pur-
poses, and to increase awareness among individual com-
munity pharmacists about their own performance. Since
2008, data on specific indicators have been collected from
all community pharmacies in the Netherlands. All indicator
scores were self-reported by pharmacists. To stimulate
internal quality improvement, community pharmacists were
annually given feedback reports with their own scores rel-
ative to those of the other pharmacists in the Netherlands.
As of 2010 other major stakeholders were involved in the
quality measurement of community pharmacies. Beside
community pharmacists and the Healthcare Inspectorate,
this included representatives of patient and consumer orga-
nizations and health insurance companies. These parties
were primarily interested in information that enabled
patients to make a conscious choice of pharmacy based on
performance. Thus beside internal quality assessment the set
of quality indicators had to facilitate also external compar-
isons between pharmacies. Consequently under the super-
vision of a national steering body and with involvement of
all major stakeholders an instrument was developed and
used to validate the 2011 set for content validity, absence of
selection or measurement bias, and statistical reliability [11].
This set of quality indicators was then thoroughly revised.
Information for the resulting 2012 set was requested from all
Dutch community pharmacies in 2013.
The comprehensive set of quality indicators for Dutch
community pharmacies and it’s results may be useful for
other countries and healthcare systems to increase aware-
ness of individual community pharmacists about their own
performance, improve supervision by the healthcare
inspectorate and enable patients and health insurance
companies to differentiate between pharmacies on the basis
of performance.
Aim of the study
This study aimed to present a comprehensive quality
indicator set for community pharmacies and to report the
scores for these indicators as supplied by the majority of
Dutch community pharmacies. In subanalyses the score
development over 5 years was described for those indica-
tors, that have been surveyed earlier, and the score con-
sistency within one pharmacy over time was assessed.
Ethics approval
Data of pharmacists and patients were coded and anonymised
prior to analysis. Use of observational data in descriptive
retrospective studies in the Netherlands is not considered as
an interventional trial according to Directive 2001/20/EC and
to Dutch legislation, and therefore does not need to be sub-
mitted to a medical ethic committee for approval.
Methods
Study design
In this retrospective study information on the validated
quality indicator set for the year 2012 was used. This
information was requested in 2013 from all 1981 Dutch
community pharmacies at that time [12]. Scores were
calculated as a cross-sectional measurement of the quality
of pharmaceutical care in the Netherlands.
For indicators that were measured as well in the prior
4 years and remained unchanged during the study period, in
a longitudinal analysis the development of scores during the
whole study period of 5 years was described and the score
consistency within one pharmacy during time was assessed.
Setting for data collection
On average, each pharmacy served around 8000 clients in
2012 [12]. In the Netherlands clients mostly visit one
Int J Clin Pharm (2016) 38:870–879 871
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particular community pharmacy [13]. All clients are reg-
istered in the pharmacy information system.
Community pharmacists in the Netherlands have a legal
and professional responsibility to optimize the safe and
effective use of medication, in cooperation with the pre-
scribers. This implies that pharmacists can intervene if a
prescribing does not follow the guidelines or does not seem
suitable for an individual patient. According to their
responsibility to ensure safe and effective medication use,
pharmacists generally had high intrinsic motivation to
explore their performance in providing pharmaceutical
care.
Data have been collected using this national survey for
5 years, and annual participation is a condition for
receiving a quality management certificate. The healthcare
inspectorate specifically visits any non-responders. The
process of data collection was widely announced in pro-
fessional circles. Although reporting on indicators was
voluntary, the relevance of providing data for both internal
quality assessment and external accountability was
emphasized in all communications [14–17].
Quality indicator survey tool
All Dutch community pharmacies were invited to complete
the online quality indicator survey on 2012 between April
and May 2013. This included 66 indicators within ten
categories: ‘Quality management’, ‘Continuity of care’,
‘Communication with the patient’, ‘Clinical risk manage-
ment’, ‘Compounding’, ‘Dispensing’, ‘Follow up of phar-
macotherapy guidelines’, ‘Counseling’, ‘Logistics’, and
‘Training of pharmaceutical staff’. Information on each
aspect was provided by the responsible pharmacist.
The quality indicators measured the presence of quality
systems (‘structures’) and the performance of processes. As
information on the clinical consequences of pharmaceutical
care for individual patients was not available, outcomes of
dispensings for patient groups were used as ‘outcome’
indicators (e.g. the concomitant use of interacting drugs or
the absence of concomitant preventive co-medication).
The online survey contained automated controls, for
example to prevent reporting of percentages above 100 %
and to alert for missing scores. It also provided pharmacists
with background information about specific quality indi-
cators when necessary. Pharmacists could also obtain
support from technical and professional helpdesks by
e-mail or telephone.
Concurrent source of dispensing outcomes
for quality indicator score validation
Information for numerical indicators based on the outcomes
from dispensing to individual patients could also be
measured by routinely-collected data from the Dutch
Foundation of Pharmaceutical Statistics (SFK). The SFK
collects drug dispensing data for nearly all community
pharmacies [12]. Using validated algorithms, the indicators
were calculated for each community pharmacy from the
dispensing data delivered to the SFK, and median (50th
percentile), 10th and 90th percentiles were available as
quality indicator scores from that source. For answering the
online survey, pharmacists could use the information from
their own pharmacy information system or they could
retrieve their indicator scores as pre calculated by the SFK
from their dispensing data through a secure website of SFK.
Data analysis
Scores on the 2012 set were either expressed as categorical
variables (yes/no) or as numerical variables (either a
number or a proportion). Scores of categorically-measured
quality indicators were given as the percentage of phar-
macies reporting the presence of a quality aspect. For
numerical quality indicators, the mean of the scores was
reported, and the variance in answers was expressed as the
5th and 95th percentile.
For the longitudinal analyses, data from the pharmacies
responding to the 2012 set were linked to their corre-
sponding scores from the previous 4 years. Ten quality
indicators (five on structures, one on process and four on
dispensing outcomes) were surveyed in the same way over
all five study years. For these quality indicators, the scores
were also calculated for the preceding years.
The intra-class correlation coefficient (ICC) was calcu-
lated to compare the variance of scores for individual
pharmacies over time (indicating changes over time for a
particular pharmacy) to the overall variation in scores over
the same period. The ICC is an indication of the correlation
of scores for a quality indicator reported over time from the
same pharmacy. The ICC could be calculated from logistic
(for categorical indicators) and linear (for continuous
indicators) mixed model analysis [18]. In this analyses, the
repeatedly measured scores for an indicator were clustered
within individual pharmacies. For continuous variables, the
ICC can be calculated by dividing the variance of scores
between community pharmacies by the total variance,
where the total variance is defined as the sum of the vari-
ance between and within pharmacies [18]. For dichoto-
mous variables, the ICC can be calculated with an
additional equation [18]. The ICC can take values between
0 and 1. A high ICC (close to 1) means that the scores
changed little for an individual pharmacy over time com-
pared with the total variance in scores of all community
pharmacies.
Descriptive statistics were performed with PASW
statistics 20.0 (IBM Corp., Chicago, IL, USA). Stata SE-
872 Int J Clin Pharm (2016) 38:870–879
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2009 (StataCorp LP Statistics/Data Analysis StataCorp,
Texas, USA) was used to assess the ICC.
Results
Information was provided by 1739 of the 1981 Dutch
community pharmacies (88 %). Table 1 gives the charac-
teristics of the community pharmacies providing information
for the quality indicator set on 2012. On average, each
employed 1.3 pharmacists and 6.4 pharmacy technicians.
Most pharmacies had a separate room for counseling and
participated in night and weekend services. Two-thirds of
them cooperated with other healthcare providers in a struc-
tured way. One-third also supplied nursing homes. One-third
compounded medication within their pharmacy and\5 %
also supplied other pharmacies with such preparations.
Table 2 shows the 66 quality indicators across 10 cate-
gories, and their scores on the presence of quality struc-
tures, the degree to which pharmacies followed
recommended procedures and outcomes from dispensing to
individual patients. Within the set, 29 indicators measured
the presence of structures, 24 focused on processes and 13
covered dispensing outcomes. Indicator scores showed
high volumes for the presence of quality structures. For the
presence of quality structures for instance, 84 % reported
the presence of a validated quality certificate (QI 1.1), and
94 % responded that they had patients’ experiences within
the past 3 years evaluated by a professional external party
(QI 1.2). The presence of structures providing information
about patients’ actual drug use (QI 2.1), contraindications
(QI 4.3) and allergic reactions (QI 4.4) were reported by
more than 95 % of those responding.
Scores were lower for processes and dispensing out-
comes, and the intervals between the 5th and 95th percentile
were broad for indicators measured on a numerical scale.
For instance, the process indicator ‘Percentage of patients
older than 70 years with at least five different drug classes in
chronic concomitant use, for whom the pharmacist
contributed to the exchange of actual drug use information
between the general practitioner and the hospital’ (QI 2.3)
had a mean of 55 % with a range between the 5th and 95th
percentile between 0 and 100 %. The outcome of dispensing
indicator ‘Percentage of patients using opioids with con-
comitant laxatives’ (QI 7.3.1) had a mean of 54 % with a
range between the 5th and 95th percentile from 35 to 75 %.
For longitudinal subanalyses on the development of
scores during time and trends in score development of
individual pharmacies, ten quality indicators were avail-
able (Table 3). Overall, the scores for these indicators
improved from 2008 to 2012. As an example for the score
development of the categorical indicator, ‘Participation in
pharmacotherapy audit meetings on a regular basis and
with specific agreements’ improved from 78 % in 2008 to
85 % in 2012 (QI 2.2.2). An example for a categorical
indicator is the ‘Mean percentage of patients with a first
dispensing of inhalation medication who had been offered
information about its use’ (QI 3.1). This score increased
from 58 % in 2008 to 70 % in 2012 Scores of those quality
indicators, which were measured repeatedly, but not in all
years, generally also improved (data not shown). The ICCs
for the quality indicators had a range between 0.01 for
‘number of coumarin users with concomitant use of co-
trimoxazole’ (QI 4.7) and 0.90 for the ‘presence of a valid
quality management certificate’ (QI 1.1) (Table 2).
Comparison of the self reported indicator scores to the
scores measured by the SFK as an independent third party
from routinely-collected dispensing data showed a high
agreement between the two sources ‘‘Appendix’’ section.
Discussion
A comprehensive set of 66 quality indicators across 10
categories was developed by pharmacists and major
stakeholders to continuously improve pharmaceutical care
and to compare indicator scores between community
pharmacies. Existing quality sets have been developed for
Table 1 Characteristics of Dutch community pharmacies
Mean full time equivalent (38-h working week) pharmacists employed per pharmacy (5th and 95th percentile) 1.36 (0.8; 2.4)
Mean full time equivalents (36-h working week) pharmacy technicians employed per pharmacy (5th and 95th percentile) 6.37 (2; 12)
Percentage of community pharmacies with a separate room available for counselling 96.4
Percentage of community pharmacies that supply nursing homes 31.1
Percentage of community pharmacies that participate in night and weekend services 99.2
Percentage of community pharmacies that cooperate with other pharmacists and healthcare providers for pharmaceutical
care in a structured way
70.2
Percentage of community pharmacies that compound medicines within the pharmacy 30.9
Percentage of community pharmacies that supply of compounded medications to more than one other pharmacy 4.1
Based on the answers of 1739 community pharmacies who completed the questionnaire for the quality indicator set in 2012
Int J Clin Pharm (2016) 38:870–879 873
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Table 2 Scores for the quality indicator set for community pharmacies in 2012
Scorea Type
1. Quality management
1.1 Presence of a valid quality management certificateb 84.4 S
1.2 Evaluating patients’ experiences within the past 3 yearsb 93.9 S
1.3.1 Availability of a procedure for registration of errors (e.g. wrong dosage, wrong substance, wrong
compounding) that occurred during the work process in the pharmacy and that were realized before the drug
reached the patientb
73.2 S
1.3.2 Number of registered errors which occurred during the dispensing of medication and that occurred during the
work process in the pharmacy and that were realized after the drug reached the patientc
42.2 (0; 205) P
1.4 Presence of a registration system for errors that occurred during the work process within the pharmacy and that
did reach the patientb
98.8 S
1.5 Number of registered errors that did reach the patientc 18.0 (0; 64) P
1.6 Number of registered complaints made by patientsc 29.1 (0; 150) P
1.7 Number of registered errors reported to a national registration of errorsc 1.5 (0; 3) P
2. Continuity of care
2.1 Attitude of the pharmacist to obtain information on patients’ actual drug use before dispensing and to register
this information in the patients’ recordb
95.0 S
2.2.1 Participation in pharmacotherapy audit meetings with general practitioners (GPs)b 98.7 S
2.2.2 Participation in pharmacotherapy audit meetings on a regular basis and with specific agreementsb 84.6 S
2.3 Percentage of patients older than 70 years with at least 5 different drug classes in chronic concomitant use, for
whom the pharmacist contributed to the exchange of actual drug use information between the general practitioner
and the hospitalc
54.7 (0; 100) P
2.4 The pharmacy staff always informs the anticoagulation directly in case of dispensing co-trimoxazole to a
coumarin userb
99.5 S
3. Communication with the patient
3.1 Percentage of patients with a first dispensing of inhalation medication who had been offered information about
its usec
70.0 (4; 100) P
3.2 Percentage of users of inhalation medication with subsequent use of oropharyngeal antimycoticsc 1.48 (0.5; 16) O
3.3 Presence of individual education programs and plans for every pharmaceutical staff memberb 94.6 S
4. Clinical risk management
4.1 Parameters for clinical risk management in the pharmacy information system are implemented according to
prevailing guidelinesb
98.8 S
4.2 In case of an interaction actions taken are electronically registered 97.9 S
4.3 Availability of protocols for informing on contra indications for all patients, especially for new patientsb 98.6 S
4.4 Availability of protocols for informing on allergic reactions for all patients, especially for new patientsb 98.9 S
4.5 Availability of protocols to check on the dosage of active components for compounded medication for children
up to 6 yearsb
97.5 S
4.6 Dosage in compounded mediation for children up to 6 years is checked by the pharmacist in at least 80 % of all
compounding for children younger than 6 yearsb
83.9 P
4.7 Absolute number of coumarin users with concomitant use of co-trimoxazolec 0.69 (0; 2) O
5. Compounding
5.1 Availability of written agreements on responsibilities for external compounding on checking the weight of
capsules, analytical tests of samples and a final control by a pharmacistb
96.5 S
5.2 Availability of a standard operation procedure for the release of compounded medication before dispensing to
the patientb
98.8 S
5.3.1 Percentage of medication compounded for individual patients for which a standardized procedure was
followedc
75.4 (6; 100) P
5.3 2 Percentage of compounding of batches with a validated procedure followed of all batch compoundingc 87.9 (16; 100) P
6. Dispensing
6.1.1 Availability of automated dose dispensing for eligible patientsb 92.0 S
6.1.2 If automated dose dispensing was used the actual guideline was followed by as well the pharmacist as the
supplierb
98.9 S
6.2 For weekly dosed trays a system was available to control on drug use as prescribed 97.5 S
874 Int J Clin Pharm (2016) 38:870–879
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Table 2 continued
Scorea Type
7. Follow up of pharmacotherapy guidelines
7.1.1 Percentage NSAID users[70 years with concomitant gastroprotectionc 84.7 (70; 96) O
7.1.2 Action was taken by the pharmacist in at least 80 % of the cases to add gastroprotection to NSAID
users[70 years for whom this co-medication was lackingb
32.3 P
7.2.1 Percentage of patients using nitrates with concomitant antithrombotic medicationc 93.0 (86; 100) O
7.2. Action was taken by the pharmacist in at least 80 % of the cases to add antithrombotic medication to nitrate
users for whom this co-medication was lackingb
18.0 P
7.3.1 Percentage of patients using opioids with concomitant laxativesc 54.1 (35; 76) O
7.3.2 Action was taken by the pharmacist in at least 80 % of the cases to add laxatives to opioid users in whom this
co-medication was lackingb
14.3 P
7.4 Percentage of patients under 6 or above 70 years of age with asthma inhalers and an additional inhalation device
dispensed during the previous 24 monthsc
69.0 (49; 86) O
7.5 Percentage of simvastatin as the first statin dispensedc 67.0 (34; 93) O
7.6 Percentage of cardiovascular patients with concomitant statin usec 75.7 (68; 83) O
7.7 Percentage of triptan users without overuse within all triptan usersc 93.3 (87; 99) O
7.8 Percentage of first dispensings of hypnotics with an amount for less than 15 days within all first hypnotic
dispensingsc
69.9 (47; 91) O
7.9 Percentage of proton pump inhibitor (PPI) users with preferred PPIs according to national guidelines within all
PPI usersc
82.2 (71; 91) O
7.10 Percentage of first dispensings of generic diclofenac, ibuprofen or naproxen within all first NSAID
dispensingsc
84.7 (67; 96) O
7.11 Percentage of COXib users without co-medication related to ischemic cardiovascular diseases within all
COXib usersc
83.4 (73; 94) O
7.12.1 The pharmacist followed additional courses for the performance of Medication Reviewsb 73.8 P
7.12.2 Medication Reviews are performed according to the professional guideline in cooperation with GPs and
patientsb
92.6 S
7.12.3 Performance of at least 20 Medication Reviews according to the professional guideline in cooperation with
GPs and patientsb
57.3 P
8. OTC counseling
8.1 Medication surveillance is conducted according to professional protocolsb 99.6 S
8.2.1 Percentage of filled protocols for patient counseling within first dispensing of orlistatc 76.9 (0; 100) P
8.2.2 Percentage of filled protocols for patient counseling within first dispensing of dextromethorphanc 66.9 (0; 100) P
8.2.3 Percentage of filled protocols for patient counseling within first dispensing of hypericumc 64.6 (0; 100) P
8.2.4 Percentage of filled protocols for patient counseling within first dispensing of domperidonc 70.5 (0; 100) P
8.2.5 Percentage of filled protocols for patient counseling within first dispensing of hydrokininc 67.5 (0; 100) P
9. Logistics
9.1 Suppliers of compounding material were assessed according to the professional guidelineb 99.4 S
9.2 Percentage of suppliers for compounding or package material that were assessed for their reliability as stated by
the guideline for reliable supplier sc
74.6 (13;100) S
9.3 Availability of a valid system to check on expired drugsb 99.7 S
9.4 Official drug recalls were performedb 99.8 S
9.5.1 Number of relevant recalls received in calendar in questionc 8.0 (0;15) P
9.5.2 Number of not completely finished recallsc 0.9 (0; 8) P
9.5.3 Not completed drug recalls were due to a too high effort to address patientsb 3.7 P
9.6.1 Number of internally reported expired medication before the drug was dispensedc 1.8 (0; 7) P
9.6.2 Number of dispensed expired medication that was reported by the patient and thus was noticed after
dispensingc
1.8 (0; 2) P
10. Training of pharmaceutical staff
10.1.1 Percentage of pharmaceutical staff with a personal development planc 60.0 (0; 100) S
10.1.2 Percentage of pharmacy technicians who were registered in a central quality registration system for
educationc
33.4 (0; 100) S
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specific diseases, such as urinary tract infections [19,]
vulnerable patients such as children and older people, and
specific settings such as nursing homes [20–26]. Other
indicators on the quality of drug prescribing and dispensing
mostly focused on drug use patterns [26–28] or described
to what extent specific guidelines and recommendations
have been followed [28–30].
The scores on this set of validated quality indicators
supplied by 88 % of all community pharmacies provided
insight into the pharmaceutical care performance of com-
munity pharmacies in the Netherlands. All indicators in the
set assessed for 2012 and measured in the four preceding
years showed a general improvement from 2008 to 2012.
Small to moderate effects on professional practice have
been previously described for audit and feedback [31].
A Cochrane review on the effects of audit and feedback
reported a median change of 1.3 % in numeric outcomes,
with an interquartile range of 1–29 % [32]. The changes in
the indicator scores in our study were consistent with these
results.
Structures to facilitate pharmaceutical care processes
and dispensing outcomes for individual patients were pre-
sent in at least 80 % of all Dutch community pharmacy. In
this the presence of a valid quality certificate is the most
meaningful, as this was acknowledged from a third,
authorized party by national standards [33].
Scores for indicators for processes and dispensing out-
comes were between 50 and 90 %. In principle, scores
below 100 % suggest potential for improvement. Full
compliance with treatment guidelines for all patients at risk
Table 2 continued
Scorea Type
10.2 Participation in a national program for patient reported side effects drugs of the national pharmacovigilance
centerb
87.5 S
10.3 Number of patient reported side effects announced to the national pharmacovigilance centerc 1.4 (0; 5) P
10.4 Percentage of employees involved in pharmaceutical care that followed an education in communication skillsc 32.2 (0; 100) S
Based on the answers of 1739 community pharmacies
S, system indicator; P, process indicator; O, outcome of dispensing indicator
a For numerical quality indicators, scores for the 5th and 95th percentiles are given in brackets
b Categorical indicators are given as percentage of community pharmacies answering ‘yes’
c Numerical quality indicators are given as the mean of the absolute numbers or percentages given as answers
Table 3 Trends in quality indicator scores over 5 years of measurement
Type 2008 2009 2010 2011 2012 ICCa
Categorical quality indicators (percentage of community pharmacies with a positive answer within all given answers)
1.1 Presence of a valid quality management certificate S 63.3 67.6 75.2 83.0 84.4 0.90
1.2 Evaluation of patients’ experiences within the past three years S 86.7 81.6 84.4 92.8 93.9 0.48
2.2.2 Participation in pharmacotherapy audit meetings on a regular basis and with specific
agreements
S 77.7 78.8 80.6 86.2 84.6 0.18
4.3 Availability of protocols for informing on contra indications for all patients, especially
new ones
S 74.3 89.7 91.5 96.3 98.6 0.89
7.12.3 Medication Reviews are performed according to the professional guideline in
cooperation with GPs and patients
S 20.3 26.3 39.6 50.3 57.3 0.14
Numerical quality indicators (mean of numbers of percentages)
3.1 Percentage of patients with a first dispensing of inhalation medication who had been
offered information about its use
P 57.9 68.5 72.9 67.4 70.0 0.45
4.7 Absolute number of coumarin users with concomitant use of co-trimoxazole O 18.2 1.12 0.75 0.71 0.69 0.01
7.1.1 Percentage NSAID users[70 years with concomitant gastro protection O 70.8 76.8 81.8 84.0 84.7 0.54
7.2.1 Percentage of patients using nitrates with concomitant antithrombotic medication O 75.8 84.9 90.9 92.0 93.0 0.46
7.3.1 Percentage of patients using opioids with concomitant laxatives O 44.5 52.6 52.8 56.1 54.1 0.51
Based on data from 1739 community pharmacies (88 % of all Dutch community pharmacies in 2012)
S, presence system indicator; P, process indicator; O, outcome of dispensings indicator
a ICC, Intra Class Coefficient, reflecting score variance within pharmacies compared with the total score variance
876 Int J Clin Pharm (2016) 38:870–879
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is, however, unrealistic, and levels may also differ across
indicators. For instance, the indicator ‘Percentage of
patients using nitrates with concomitant antithrombotic
medication’ (QI 7.2.1) had a score of 93 % in 2012, which
had improved continuously from 76 % in 2008. Possibly
this is the highest score to achieve in clinical practice for a
patient population. The mean percentage of patients on
opioids with concomitant use of laxatives (QI 7.3.1)
remained between 45 and 56 % without a clear trend over
time. The reasons for the deficient implementation of this
recommendation should be studied in clinical practice.
Confidence intervals for the numerical indicators
showed considerable variation and suggested differences in
the performance of individual community pharmacies.
Substantial changes in the scores of individual pharmacies
were seen over time for users with the unfavorable com-
bination of coumarin with co-trimoxazole (QI 4.7): in
2008, pharmacies had on average 18 coumarin users co-
medicating with co-trimoxazole, but this had decreased
dramatically by 2012, to an average of less than one per
pharmacy. The low ICC of 0.01 shows that the absolute
numbers reported by individual pharmacies for this inter-
action varied considerable over time, probably due to the
huge decrease in numbers between 2008 and 2009 within
all pharmacies. As the interaction of coumarin with co-
trimoxazole should be avoided, this decrease means a
substantial improvement in dispensing outcomes for
patients [34]. This improvement might be due to increased
awareness among community pharmacies resulting from
the feedback reports on the first indicator assessment. It
might also be due to extra alertness for this interaction by
prescribers due to the new recommendations from litera-
ture [34].
The scores for the other quality indicators on the out-
comes of dispensing processes (QI 7.11, QI 7.21, QI 7.3.1)
measured percentages of patients co-medicated according
to the guidelines. For these indicators, at least some con-
sistency in the scores reported by individual pharmacies
over time was suggested by ICCs between 0.46 and
0.54.The ICCs showed stable scores over time within
individual pharmacies for the presence of systems such as a
quality management certificate and the availability of
protocols to provide information about contraindications
(ICC for both aspects was 0.9).Further research should
examine what factors might contribute to improvements in
individual pharmacies and why some indicator scores
improved more than others.
Strengths and limitations
A key strength of our study was that information was
available from 88 % of all Dutch community pharmacies.
Sub-analysis on the 12 % of non-responders in 2012 for
their scores reported in previous years, however, showed
lower scores on all quality indicators than the scores of the
pharmacies included in our study. The scores presented
here might therefore tend to overestimate the quality of
care for community pharmacies in the Netherlands to some
extent.
As all quality indicator scores were self-reported by
community pharmacists, some of the indicators, especially
on the presence of structures and processes, are too easy to
claim without actually performing in the desired way. This
attitude might be furthermore influenced by an increasing
awareness of quality resulting from pay-for-performance
policies of health insurance companies could have caused a
bias in the scores towards the desired outcomes. Bias from
inappropriate reporting of quality indicator scores was also
assumed in the measurements of GP scores in the UK [35].
We therefore compared those scores that could be checked
with scores calculated in a uniform way by a third party from
routinely-collected dispensing data of SFK. These indicators
on the outcomes of dispensing could thus not be claimed
from self assessment by the pharmacists. The scores from the
two sources were in agreement and there was no evidence of
structural higher reported scores from self-assessment ‘‘Ap-
pendix’’ section. We therefore consider it unlikely that
reporting bias influenced the scores presented here.
Conclusion
A set of quality indicators provided insight into the quality of
pharmaceutical care at a national level for pharmacists, health
care inspectorate, health insurance companies and patient
organizations. Especially the presence of quality structures
improved, and as of 2012 they were present in at least 80 %
of the community pharmacies. Scores on care processes and
on outcomes of dispensing varied between individual phar-
macies and over time. These findings can be used in future
research to understand the reasons for differences in quality
improvement between individual pharmacies.
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